Introduction: Since the COVID-19 outbreak, there have been studies showing the impact of the disease on other respiratory diseases, leading to an impact on prevention and treatment. Therefore, it is necessary to analyze data on disease patterns and hospital drug lists in order to have data as a basis for adjustment for the periods during and after the epidemic, and to meet the treatment needs that may change. Methods: In this study, we collected information from the drug supply, treatment activities, drug used and value. Drug categories and ABC analysis were used for drug formulary. ICD-10 (International Classification of Diseases 10th Revision) classification was used to analyze disease pattern. Other supporting data on drug supply activities were also used, contributing to the findings. Results and discussion: The disease pattern represents the intensive professional activities of the respiratory hospital. The disease with the highest proportion is pulmonary tuberculosis. Another respiratory disease accounted for a large proportion is COPD (Chronic obstructive pulmonary disease). The results of drug formulary analysis indicated that the hospital has developed a reasonable drug list, consistent with the disease pattern before the time of the COVID-19 pandemic. Low inventory value indicated that drug planning is close to reality. These data also suggested that further research on supportive regimens for COPD treatment in case of pulmonary disease occurrence, such as COVID-19 is required. Conclusion: This study provides pre-pandemic data to serve as the basis for future comparative studies and to identify further research directions in response to the periods during and after COVID-19. Research data also suggested the potential risks of stockpiling, inventory, as well as increasing the use of domestic drugs may be more proactive in drug supply